Hydra Biosciences, Inc.To Present At The JMP Securities Life Sciences Conference On June 22

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Hydra Biosciences, a leader in the field of Transient Receptor Potential (TRP) ion channel modulation to treat pain, inflammation, renal disease, CNS and pulmonary diseases, today announced that Russell Herndon, President and CEO, will provide a company update at the JMP Securities Life Sciences Conference. The presentation is June 22, 2016 at 11:30 a.m. EST at the St. Regis in New York City.

JMP Securities’ Life Sciences Conference matches institutional investors with publicly traded and privately held companies in the areas of biotechnology, specialty pharmaceuticals, medical devices, life science tools and diagnostics.

About Hydra Biosciences
Hydra Biosciences is a privately held biopharmaceutical company based in Cambridge, Massachusetts, that develops drugs to treat pain, inflammation, renal disease, CNS and pulmonary disease using its expertise in novel ion channels. Hydra Biosciences’ proprietary platforms enable the company to identify and develop drug candidates that address significant unmet medical needs. More information about Hydra Biosciences is available at: www.hydrabiosciences.com. Follow the company @HydraBio.